invitae
pacific
biosciences
collaborate
develop
whole
genome
assays
pediatric
epilepsy
diagnostics
nasdaq
pacb
san
francisco
menlo
park
globe
newswire
invitae
corporation
nyse
nvta
leading
genetics
company
pacific
biosciences
california
nasdaq
pacb
leading
provider
sequencing
genomes
transcriptomes
epigenomes
today
announced
research
collaboration
focused
investigation
clinically
relevant
molecular
targets
use
development
advanced
diagnostic
testing
epilepsy
support
collaboration
invitae
expanding
pacbio
sequencing
capacity
meet
growing
demand
clinical
applications
dependent
highly
accurate
genomic
information
half
epilepsies
traced
genetic
cause
child
presents
seizures
genetic
testing
help
identify
underlying
often
rare
conditions
early
genetic
testing
may
direct
accurate
diagnostic
tool
children
shortening
lengthy
diagnostic
odysseys
delays
diagnosis
devastating
children
genetic
epilepsies
neurodegenerative
early
symptoms
may
subtle
easy
misdiagnose
invitae
behind
program
prominent
collaborative
program
developed
provide
faster
diagnosis
young
children
epilepsy
many
regions
around
world
estimated
nearly
million
people
living
diagnosed
epilepsy
worldwide
underlying
cause
remains
unknown
approximately
half
individuals
said
robert
nussbaum
md
chief
medical
officer
invitae
identifying
many
underlying
genetic
causes
epilepsy
becoming
increasingly
critical
overall
clinical
management
prognosis
research
collaboration
pacbio
invitae
aims
develop
innovative
methods
provide
accurate
answers
individuals
living
epilepsy
healthcare
first
phase
research
collaboration
invitae
pacbio
focused
whole
genome
sequencing
study
large
pediatric
epilepsy
patient
cohort
derived
behind
program
sequencing
performed
using
pacbio
highly
accurate
sequencing
technology
known
hifi
sequencing
generate
comprehensive
variant
profiles
used
investigate
genetic
etiology
epilepsy
research
intended
accelerate
invitae
development
assays
help
patients
unable
get
diagnosis
conventional
sequencing
technologies
facilitate
improved
treatment
options
based
specific
genetic
targets
honored
partner
invitae
recognized
leader
genetics
methods
potential
support
earlier
genetic
testing
intervention
aid
treatment
selection
millions
people
living
epilepsy
worldwide
said
christian
henry
chief
executive
officer
pacbio
working
leading
organizations
invitae
important
part
strategy
accelerate
use
highly
accurate
sequencing
platform
whole
genome
sequencing
behind
behind
seizure
innovative
collaboration
designed
increase
access
genetic
testing
children
experience
unprovoked
seizures
childhood
united
states
canada
half
epilepsies
genetic
basis
often
associated
rare
neurodegenerative
conditions
symptoms
early
genetic
testing
may
direct
accurate
diagnostic
tool
participants
behind
seizure
program
diagnosed
one
two
years
sooner
reported
averages
program
established
biomarin
invitae
includes
biogen
encoded
therapeutics
neurocrine
biosciences
neurogene
praxis
precision
medicines
ptc
therapeutics
stoke
therapeutics
taysha
gene
therapies
xenon
pharmaceuticals
learn
behind
seizure
program
please
visit
https
en
behindtheseizure
invitae
invitae
corporation
nyse
nvta
leading
genetics
company
whose
mission
bring
comprehensive
genetic
information
mainstream
medicine
improve
healthcare
billions
people
invitae
goal
aggregate
world
genetic
tests
single
service
higher
quality
faster
turnaround
time
lower
prices
information
visit
company
website
pacific
biosciences
pacific
biosciences
california
nasdaq
pacb
empowering
life
scientists
highly
accurate
sequencing
company
innovative
instruments
based
single
molecule
sequencing
technology
delivers
comprehensive
view
genomes
transcriptomes
epigenomes
enabling
access
full
spectrum
genetic
variation
organism
cited
thousands
publications
sequencing
systems
use
scientists
around
world
drive
discovery
human
biomedical
research
plant
animal
sciences
microbiology
information
please
visit
follow
pacbio
pacbio
products
research
use
use
diagnostic
procedures
statements
statements
press
release
historical
statements
including
among
things
statements
relating
market
leadership
uses
accuracy
quality
performance
benefits
using
products
technologies
including
smrt
technology
suitability
utility
methods
products
technologies
particular
applications
projects
expected
benefits
expected
achievement
goals
research
collaboration
invitae
ability
company
successful
reaching
technological
commercial
potential
future
events
place
undue
reliance
statements
involve
known
unknown
risks
uncertainties
changes
circumstances
factors
cases
beyond
pacific
biosciences
control
could
cause
actual
results
differ
materially
information
expressed
implied
statements
made
press
release
factors
could
materially
affect
actual
results
found
pacific
biosciences
recent
filings
securities
exchange
commission
including
pacific
biosciences
recent
reports
forms
include
listed
caption
risk
pacific
biosciences
undertakes
obligation
revise
update
information
press
release
reflect
events
circumstances
future
even
new
information
becomes
available
contacts
invitae
laura
pr
pacbio
media
colin
sanford
colin
investors
trevin
rard
ir
